University Library
  • Login
A gateway to Melbourne's research publications
Minerva Access is the University's Institutional Repository. It aims to collect, preserve, and showcase the intellectual output of staff and students of the University of Melbourne for a global audience.
View Item 
  • Minerva Access
  • Medicine, Dentistry & Health Sciences
  • Melbourne Medical School
  • Medicine and Radiology
  • Medicine and Radiology - Research Publications
  • View Item
  • Minerva Access
  • Medicine, Dentistry & Health Sciences
  • Melbourne Medical School
  • Medicine and Radiology
  • Medicine and Radiology - Research Publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

    Activated platelets in the tumor microenvironment for targeting of antibody-drug conjugates to tumors and metastases

    Thumbnail
    Download
    Published version (2.178Mb)

    Citations
    Scopus
    Web of Science
    Altmetric
    4
    3
    Author
    Yap, ML; McFadyen, JD; Wang, X; Ziegler, M; Chen, Y-C; Willcox, A; Nowell, CJ; Scott, AM; Sloan, EK; Hogarth, PM; ...
    Date
    2019-01-01
    Source Title
    Theranostics
    Publisher
    IVYSPRING INT PUBL
    University of Melbourne Author/s
    Hogarth, Phillip; Scott, Andrew; Yap, May Lin; Wang, Xiaowei; Chen, Yung-Chih; Peter, Karlheinz
    Affiliation
    Medicine and Radiology
    Clinical Pathology
    Metadata
    Show full item record
    Document Type
    Journal Article
    Citations
    Yap, M. L., McFadyen, J. D., Wang, X., Ziegler, M., Chen, Y. -C., Willcox, A., Nowell, C. J., Scott, A. M., Sloan, E. K., Hogarth, P. M., Pietersz, G. A. & Peter, K. (2019). Activated platelets in the tumor microenvironment for targeting of antibody-drug conjugates to tumors and metastases. THERANOSTICS, 9 (4), pp.1154-1169. https://doi.org/10.7150/thno.29146.
    Access Status
    Open Access
    URI
    http://hdl.handle.net/11343/253772
    DOI
    10.7150/thno.29146
    Abstract
    Rationale: Platelets are increasingly recognized as mediators of tumor growth and metastasis. Hypothesizing that activated platelets in the tumor microenvironment provide a targeting epitope for tumor-directed chemotherapy, we developed an antibody-drug conjugate (ADC), comprised of a single-chain antibody (scFv) against the platelet integrin GPIIb/IIIa (scFvGPIIb/IIIa) linked to the potent chemotherapeutic microtubule inhibitor, monomethyl auristatin E (MMAE). Methods: We developed an ADC comprised of three components: 1) A scFv which specifically binds to the high affinity, activated integrin GPIIb/IIIa on activated platelets. 2) A highly potent microtubule inhibitor, monomethyl auristatin E. 3) A drug activation/release mechanism using a linker cleavable by cathepsin B, which we demonstrate to be abundant in the tumor microenvironment. The scFvGPIIb/IIIa-MMAE was first conjugated with Cyanine7 for in vivo imaging. The therapeutic efficacy of the scFvGPIIb/IIIa-MMAE was then tested in a mouse metastasis model of triple negative breast cancer. Results: In vitro studies confirmed that this ADC specifically binds to activated GPIIb/IIIa, and cathepsin B-mediated drug release/activation resulted in tumor cytotoxicity. In vivo fluorescence imaging demonstrated that the newly generated ADC localized to primary tumors and metastases in a mouse xenograft model of triple negative breast cancer, a difficult to treat tumor for which a selective tumor-targeting therapy remains to be clinically established. Importantly, we demonstrated that the scFvGPIIb/IIIa-MMAE displays marked efficacy as an anti-cancer agent, reducing tumor growth and preventing metastatic disease, without any discernible toxic effects. Conclusion: Here, we demonstrate the utility of a novel ADC that targets a potent cytotoxic drug to activated platelets and specifically releases the cytotoxic agent within the confines of the tumor. This unique targeting mechanism, specific to the tumor microenvironment, holds promise as a novel therapeutic approach for the treatment of a broad range of primary tumors and metastatic disease, particularly for tumors that lack specific molecular epitopes for drug targeting.

    Export Reference in RIS Format     

    Endnote

    • Click on "Export Reference in RIS Format" and choose "open with... Endnote".

    Refworks

    • Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References


    Collections
    • Minerva Elements Records [45689]
    • Clinical Pathology - Research Publications [385]
    • Medicine and Radiology - Research Publications [2346]
    Minerva AccessDepositing Your Work (for University of Melbourne Staff and Students)NewsFAQs

    BrowseCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects
    My AccountLoginRegister
    StatisticsMost Popular ItemsStatistics by CountryMost Popular Authors